Recovered COVID-19 patients in New Orleans area donate blood to California biotech firm working on treatment
The race to find a treatment for COVID-19 is in full swing as researchers in labs across the world attempt to unravel the unique properties of this disease, and find ways to neutralize it. To aid in the effort, recovered patients in New Orleans — a national hotspot for infections — are participating in a blood sampling study led by a California biotech firm that hopes to find an FDA-approved treatment for the disease.
Motus GI cleared to sell colon prep device in key market
Motus GI got the green light to launch its Gen2 Pure-Vu System in Israel, the company announced April 7. The Israeli Ministry of Health cleared commercial sales of the Pure-Vu system just weeks after Motus GI gained CE mark approval. The Israeli medical device market is one of the largest in the Middle East.
Creating Consistent Value in Biotech Without Diluting Stakeholders
One of the greatest challenges for pre-commercial biotech companies is consistently generating capital necessary for operating costs and for R&D of new products that provide value to stakeholders, both for investors and patients. At OSE Immunotherapeutics we implemented a business model that allows us to be one of the rare French biotech companies without commercial products able to generate revenue and advance multiple clinical stage assets without needing dilutive funding since our 2015 IPO.
Cue Biopharma Pioneers In Vivo T-Cell Enhancement
Cue Biopharma has quickly evolved into a player in the T-cell space. The company was formed in 2015, a spin-out from the Albert Einstein College of Medicine. Dan Passeri, the company CEO, has a background in oncology drug development and has worked at the National Cancer Institute. When he was asked to take over the firm in August 2016, he was employee number eight.
Why Soon-Shiong Thinks His Triangle Offense for Cancer Can Be Applied to COVID-19
Patrick Soon-Shiong likes to talk about the “triangle offense,” the activation of a combination of macrophages, natural killer cells, and memory T-cells to battle cancer. He believes the same approach he has been working to train on cancer can be enlisted in the fight against COVID-19, the virus behind today’s global pandemic. We spoke to Soon-Shiong, chairman and CEO of NantKwest, about his approach to immunotherapy, what results he’s seen to date, and why he believes what he’s learned about harnessing the immune system in the fight against cancer can be applied to treating COVID-19.
Contagion Connect Episode 7 – The ID Pipeline: Rezafungin & Antiviral Fc-Conjugates
Cidara Therapeutics is developing a new echinocandin called Rezafungin that’s shown promise in clinical trials. Cidara is also developing a new anti-viral technology which isn’t a vaccine, but could provide universal flu protection on a different basis.
Empowered by Parkinson’s
Empowered by Parkinson’s premieres on Wednesday, April 1, 2020 at 10 p.m. on CPTV. It encores on Saturday, April 11, 2020 at 7 p.m. on CPTV and Tuesday, April 21, 2020 at 10 p.m. on CPTV.
OSE Immunotherapeutics Meets Primary Endpoint in Phase III Trial for HLA-A2 Positive Lung Cancer
In Step 1 of the Phase III Atalante 1 trial, OSE Immunotherapeutics’ investigational agent Tedopi improved the 12-month survival rate over chemotherapy in patients with HLA-A2 positive non-small cell lung cancer who faile
